{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:37:38Z","timestamp":1792039058261,"version":"4.4.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T00:00:00Z","timestamp":1400544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Genet"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/nrg3742","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T03:26:36Z","timestamp":1400556396000},"page":"445-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":725,"title":["Engineering adeno-associated viruses for clinical gene therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Melissa A.","family":"Kotterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David V.","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,20]]},"reference":[{"key":"BFnrg3742_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrg3555","volume":"14","author":"KM Boycott","year":"2013","unstructured":"Boycott, K. M., Vanstone, M. R., Bulman, D. E. & MacKenzie, A. E. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nature Rev. Genet. 14, 681\u2013691 (2013).","journal-title":"Nature Rev. Genet."},{"key":"BFnrg3742_CR2","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1161\/ATVBAHA.108.175620","volume":"28","author":"ES Stroes","year":"2008","unstructured":"Stroes, E. S. et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28, 2303\u20132304 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrg3742_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosissup.2010.03.004","volume":"11","author":"D Gaudet","year":"2010","unstructured":"Gaudet, D. et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler. Suppl. 11, 55\u201360 (2010).","journal-title":"Atheroscler. Suppl."},{"key":"BFnrg3742_CR4","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1210\/jc.2011-3002","volume":"97","author":"AC Carpentier","year":"2012","unstructured":"Carpentier, A. C. et al. Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 97, 1635\u20131644 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrg3742_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1089\/hum.2008.107","volume":"19","author":"WW Hauswirth","year":"2008","unstructured":"Hauswirth, W. W. et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19, 979\u2013990 (2008).","journal-title":"Hum. Gene Ther."},{"key":"BFnrg3742_CR6","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","volume":"358","author":"JWB Bainbridge","year":"2008","unstructured":"Bainbridge, J. W. B. et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231\u20132239 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrg3742_CR7","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire, A. M. et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240\u20132248 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrg3742_CR8","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","volume":"374","author":"AM Maguire","year":"2009","unstructured":"Maguire, A. M. et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597\u20131605 (2009).","journal-title":"Lancet"},{"key":"BFnrg3742_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","volume":"130","author":"SG Jacobson","year":"2012","unstructured":"Jacobson, S. G. et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol. 130, 9\u201324 (2012).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrg3742_CR10","doi-asserted-by":"publisher","first-page":"120ra15","DOI":"10.1126\/scitranslmed.3002865","volume":"4","author":"J Bennett","year":"2012","unstructured":"Bennett, J. et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med. 4, 120ra15 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrg3742_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"RE MacLaren","year":"2014","unstructured":"MacLaren, R. E. et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. Lancet 383, 1129\u20131137 (2014).","journal-title":"Lancet"},{"key":"BFnrg3742_CR12","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani, A. C. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357\u20132365 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrg3742_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","volume":"15","author":"BE Jaski","year":"2009","unstructured":"Jaski, B. E. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1\/2 clinical trial. J. Card. Fail. 15, 171\u2013181 (2009).","journal-title":"J. Card. Fail."},{"key":"BFnrg3742_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"M Jessup","year":"2011","unstructured":"Jessup, M. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304\u2013313 (2011).","journal-title":"Circulation"},{"key":"BFnrg3742_CR15","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1128\/JVI.07232-11","volume":"86","author":"MA DiMattia","year":"2012","unstructured":"DiMattia, M. A. et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 86, 6947\u20136958 (2012).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR16","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1128\/JVI.00867-13","volume":"87","author":"L Govindasamy","year":"2013","unstructured":"Govindasamy, L. et al. Structural insights into adeno-associated virus serotype 5. J. Virol. 87, 11187\u201311199 (2013).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/mt.2011.255","volume":"20","author":"P Asuri","year":"2012","unstructured":"Asuri, P. et al. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol. Ther. 20, 329\u2013338 (2012).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gt.2011.143","volume":"19","author":"K Varadi","year":"2012","unstructured":"Varadi, K. et al. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800\u2013809 (2012).","journal-title":"Gene Ther."},{"key":"BFnrg3742_CR19","doi-asserted-by":"publisher","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","volume":"5","author":"D Dalkara","year":"2013","unstructured":"Dalkara, D. et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med. 5, 189ra76 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnrg3742_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature12875","volume":"506","author":"L Lisowski","year":"2013","unstructured":"Lisowski, L. et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506, 382\u2013386 (2013).","journal-title":"Nature"},{"key":"BFnrg3742_CR21","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1073\/pnas.0802866105","volume":"105","author":"L Zhong","year":"2008","unstructured":"Zhong, L. et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl Acad. Sci. USA 105, 7827\u20137832 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrg3742_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.virol.2008.08.027","volume":"381","author":"L Zhong","year":"2008","unstructured":"Zhong, L. et al. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381, 194\u2013202 (2008).","journal-title":"Virology"},{"key":"BFnrg3742_CR23","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","volume":"121","author":"AT Martino","year":"2013","unstructured":"Martino, A. T. et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224\u20132233 (2013).","journal-title":"Blood"},{"key":"BFnrg3742_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV\u2013factor IX and limitations imposed by the host immune response. Nature Med. 12, 342\u2013347 (2006).","journal-title":"Nature Med."},{"key":"BFnrg3742_CR25","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1128\/JVI.74.4.1761-1766.2000","volume":"74","author":"M Moskalenko","year":"2000","unstructured":"Moskalenko, M. et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74, 1761\u20131766 (2000).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR26","doi-asserted-by":"publisher","first-page":"9281","DOI":"10.1128\/JVI.74.19.9281-9293.2000","volume":"74","author":"CE Wobus","year":"2000","unstructured":"Wobus, C. E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281\u20139293 (2000).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1128\/JVI.80.2.821-834.2006","volume":"80","author":"MA Lochrie","year":"2006","unstructured":"Lochrie, M. A. et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80, 821\u2013834 (2006).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR28","doi-asserted-by":"publisher","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","volume":"5","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi, F. et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnrg3742_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/mt.2012.186","volume":"21","author":"RC M\u00fcnch","year":"2013","unstructured":"M\u00fcnch, R. C. et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther. 21, 109\u2013118 (2013).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR30","doi-asserted-by":"publisher","first-page":"28814","DOI":"10.1074\/jbc.M113.482380","volume":"288","author":"S Shen","year":"2013","unstructured":"Shen, S. et al. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J. Biol. Chem. 288, 28814\u201328823 (2013).","journal-title":"J. Biol. Chem."},{"key":"BFnrg3742_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nbt1182","volume":"24","author":"N Maheshri","year":"2006","unstructured":"Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nature Biotech. 24, 198\u2013204 (2006).","journal-title":"Nature Biotech."},{"key":"BFnrg3742_CR32","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/gt.2012.20","volume":"19","author":"MA Bartel","year":"2012","unstructured":"Bartel, M. A., Weinstein, J. R. & Schaffer, D. V. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther. 19, 694\u2013700 (2012).","journal-title":"Gene Ther."},{"key":"BFnrg3742_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/jgm.849","volume":"8","author":"L Perabo","year":"2006","unstructured":"Perabo, L. et al. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J. Gene Med. 8, 155\u2013162 (2006).","journal-title":"J. Gene Med."},{"key":"BFnrg3742_CR34","first-page":"S140","volume":"20","author":"MA Bartel","year":"2012","unstructured":"Bartel, M. A. et al. Directed evolution of AAV for enhanced evasion of human neutralizing antibodies. Am. Soc. Gene Cell Ther. 15th Annu. Meet. 20, S140 (2012).","journal-title":"Am. Soc. Gene Cell Ther. 15th Annu. Meet."},{"key":"BFnrg3742_CR35","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1073\/pnas.0813365106","volume":"106","author":"KJD Excoffon","year":"2009","unstructured":"Excoffon, K. J. D. et al. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc. Natl Acad. Sci. USA 106, 3865\u20133870 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrg3742_CR36","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/mt.2010.287","volume":"19","author":"J-H Jang","year":"2011","unstructured":"Jang, J.-H. et al. An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol. Ther. 19, 667\u2013675 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR37","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1073\/pnas.0813207106","volume":"106","author":"L Yang","year":"2009","unstructured":"Yang, L. et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl Acad. Sci. USA 106, 3946\u20133951 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrg3742_CR38","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mt.2009.292","volume":"18","author":"SJ Gray","year":"2010","unstructured":"Gray, S. J. et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood\u2013brain barrier (BBB). Mol. Ther. 18, 570\u2013578 (2010).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR39","doi-asserted-by":"publisher","first-page":"e7467","DOI":"10.1371\/journal.pone.0007467","volume":"4","author":"RR Klimczak","year":"2009","unstructured":"Klimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G. & Schaffer, D. V. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat M\u00fcller cells. PLoS ONE 4, e7467 (2009).","journal-title":"PLoS ONE"},{"key":"BFnrg3742_CR40","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/mt.2011.62","volume":"19","author":"D Dalkara","year":"2011","unstructured":"Dalkara, D. et al. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol. Ther. 19, 1602\u20131608 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj, T., Gersbach, C. A. & Barbas, C. F. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397\u2013405 (2013).","journal-title":"Trends Biotechnol."},{"key":"BFnrg3742_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ng0498-325","volume":"18","author":"DW Russell","year":"1998","unstructured":"Russell, D. W. & Hirata, R. K. Human gene targeting by viral vectors. Nature Genet. 18, 325\u2013330 (1998).","journal-title":"Nature Genet."},{"key":"BFnrg3742_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature10177","volume":"475","author":"H Li","year":"2011","unstructured":"Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217\u2013221 (2011).","journal-title":"Nature"},{"key":"BFnrg3742_CR44","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol. Ther. 19, 2152\u20132162 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR45","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2014.8","volume":"21","author":"P Colella","year":"2014","unstructured":"Colella, P. et al. Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther. 21, 450\u2013456 (2014).","journal-title":"Gene Ther."},{"key":"BFnrg3742_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/emmm.201302948","volume":"6","author":"I Trapani","year":"2014","unstructured":"Trapani, I. et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol. Med. 6, 194\u2013211 (2014).","journal-title":"EMBO Mol. Med."},{"key":"BFnrg3742_CR47","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/hmg\/ddt224","volume":"22","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum. Mol. Genet. 22, 3720\u20133729 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrg3742_CR48","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704\u2013712 (2010).","journal-title":"Hum. Gene Ther."},{"key":"BFnrg3742_CR49","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi, F. et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nature Med. 13, 419\u2013422 (2007).","journal-title":"Nature Med."},{"key":"BFnrg3742_CR50","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1099\/vir.0.014175-0","volume":"90","author":"D Madsen","year":"2009","unstructured":"Madsen, D., Cantwell, E. R., O'Brien, T., Johnson, P. A. & Mahon, B. P. Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. J. Gen. Virol. 90, 2622\u20132633 (2009).","journal-title":"J. Gen. Virol."},{"key":"BFnrg3742_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/mt.2013.218","volume":"22","author":"T-L Wu","year":"2014","unstructured":"Wu, T.-L. et al. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. Mol. Ther. 22, 42\u201351 (2014).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR52","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1172\/JCI68205","volume":"123","author":"SM Faust","year":"2013","unstructured":"Faust, S. M. et al. CpG-depleted adeno-associated virus vectors evade immune detection. J. Clin. Invest. 123, 2994\u20133001 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrg3742_CR53","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/mt.2009.181","volume":"17","author":"D Dalkara","year":"2009","unstructured":"Dalkara, D. et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol. Ther. 17, 2096\u20132102 (2009).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR54","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","volume":"72","author":"C Summerford","year":"1998","unstructured":"Summerford, C. & Samulski, R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438\u20131445 (1998).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80\u201386 (2010).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/02648725.2007.10648098","volume":"24","author":"A Ghosh","year":"2007","unstructured":"Ghosh, A. & Duan, D. Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol. Genet. Eng. Rev. 24, 165\u2013177 (2007).","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"BFnrg3742_CR57","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1128\/JVI.77.1.423-432.2003","volume":"77","author":"D Bowles","year":"2003","unstructured":"Bowles, D., Rabinowitz, J. & Samulski, R. Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. J. Virol. 77, 423\u2013432 (2003).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR58","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1128\/JVI.00254-08","volume":"82","author":"D Grimm","year":"2008","unstructured":"Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82, 5887\u20135911 (2008).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR59","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/mt.2008.167","volume":"16","author":"JT Koerber","year":"2008","unstructured":"Koerber, J. T., Jang, J.-H. & Schaffer, D. V. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 16, 1703\u20131709 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR60","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/mt.2008.100","volume":"16","author":"W Li","year":"2008","unstructured":"Li, W. et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16, 1252\u20131260 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR61","first-page":"161","volume":"434","author":"JT Koerber","year":"2008","unstructured":"Koerber, J. T. & Schaffer, D. V. Transposon-based mutagenesis generates diverse adeno-associated viral libraries with novel gene delivery properties. Methods Mol. Biol. 434, 161\u2013170 (2008).","journal-title":"Methods Mol. Biol."},{"key":"BFnrg3742_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/hum.2006.139","volume":"18","author":"JT Koerber","year":"2007","unstructured":"Koerber, J. T., Jang, J.-H., Yu, J. H., Kane, R. S. & Schaffer, D. V. Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography. Hum. Gene Ther. 18, 367\u2013378 (2007).","journal-title":"Hum. Gene Ther."},{"key":"BFnrg3742_CR63","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1038\/mt.2009.184","volume":"17","author":"JT Koerber","year":"2009","unstructured":"Koerber, J. T. et al. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol. Ther. 17, 2088\u20132095 (2009).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ymthe.2005.08.017","volume":"13","author":"G Gao","year":"2006","unstructured":"Gao, G. et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol. Ther. 13, 77\u201387 (2006).","journal-title":"Mol. Ther."},{"key":"BFnrg3742_CR65","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1089\/hum.2010.194","volume":"22","author":"P Bell","year":"2011","unstructured":"Bell, P. et al. Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum. Gene Ther. 22, 985\u2013997 (2011).","journal-title":"Hum. Gene Ther."},{"key":"BFnrg3742_CR66","volume-title":"Fields' Virology","author":"DM Knipe","year":"2007","unstructured":"Knipe, D. M. & Howley, P. M. Fields' Virology (Lippincott Williams & Wilkins, 2007)."},{"key":"BFnrg3742_CR67","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1073\/pnas.1001673107","volume":"107","author":"F Sonntag","year":"2010","unstructured":"Sonntag, F., Schmidt, K. & Kleinschmidt, J. A. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107, 10220\u201310225 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrg3742_CR68","doi-asserted-by":"publisher","first-page":"12686","DOI":"10.1128\/JVI.05359-11","volume":"85","author":"F Sonntag","year":"2011","unstructured":"Sonntag, F. et al. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol. 85, 12686\u201312697 (2011).","journal-title":"J. Virol."},{"key":"BFnrg3742_CR69","doi-asserted-by":"publisher","first-page":"10405","DOI":"10.1073\/pnas.162250899","volume":"99","author":"Q Xie","year":"2002","unstructured":"Xie, Q. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl Acad. Sci. USA 99, 10405\u201310410 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrg3742_CR70","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.gt.3302233","volume":"11","author":"TR Flotte","year":"2004","unstructured":"Flotte, T. R. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 11, 805\u2013810 (2004).","journal-title":"Gene Ther."},{"key":"BFnrg3742_CR71","doi-asserted-by":"publisher","first-page":"10613","DOI":"10.1073\/pnas.90.22.10613","volume":"90","author":"TR Flotte","year":"1993","unstructured":"Flotte, T. R. et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl Acad. Sci. USA 90, 10613\u201310617 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrg3742_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev.bioeng.10.061807.160514","volume":"10","author":"DV Schaffer","year":"2008","unstructured":"Schaffer, D. V., Koerber, J. T. & Lim, K. Molecular engineering of viral gene delivery vehicles. Annu. Rev. Biomed. Eng. 10, 169\u2013194 (2008).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"BFnrg3742_CR73","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","volume":"14","author":"Z Wu","year":"2006","unstructured":"Wu, Z., Asokan, A. & Samulski, R. J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14, 316\u2013327 (2006).","journal-title":"Mol. Ther."}],"container-title":["Nature Reviews Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrg3742.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrg3742","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrg3742.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:32:51Z","timestamp":1684452771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrg3742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,20]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFnrg3742"],"URL":"https:\/\/doi.org\/10.1038\/nrg3742","relation":{},"ISSN":["1471-0056","1471-0064"],"issn-type":[{"value":"1471-0056","type":"print"},{"value":"1471-0064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,20]]},"assertion":[{"value":"20 May 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.K. and D.V.S. are inventors on patents related to directed evolution of adeno-associated viruses.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}